Literature DB >> 9576254

Modified approach for the selective treatment of temporal lobe epilepsy: transsylvian-transcisternal mesial en bloc resection.

P Vajkoczy1, K Krakow, S Stodieck, B Pohlmann-Eden, P Schmiedek.   

Abstract

OBJECT: The authors propose a novel surgical approach for amygdalohippocampectomy (AH) in patients with temporal lobe epilepsy. Via a transsylvian-transcisternal route, the parahippocampal gyrus is directly exposed from its medial aspect, thus allowing a standardized en bloc resection of the temporomesial epileptogenic structures--the amygdala, anterior hippocampus, parahippocampal gyrus, and subiculum. Additional anatomical studies have been performed for standardization of this approach.
METHODS: From 1990 to 1996, 32 patients presenting with medically intractable mesial temporal lobe epilepsy underwent AH via the transsylvian-transcisternal approach. Preoperative computerized tomography and magnetic resonance imaging revealed temporomesial lesions in 16 patients. Histopathological examination revealed cavernous malformations in seven patients, low-grade astrocytomas in four, hamartomas in three, and gangliogliomas in two patients. Specimens obtained in patients with no lesions were diagnosed as hippocampal sclerosis in all cases. No patient experienced permanent morbidity. Nine percent of the patients developed a temporary partial oculomotor nerve palsy. Only one patient developed a postoperative visual field deficit with a contralateral quadrantanopsia. With respect to seizure outcome, all patients benefited from surgery. At follow-up evaluation (mean 26.4 months), 80% of the patients were free from seizures (Engel Class I). Eight patients in this group were no longer receiving medication. Seventeen percent had experienced only one to several seizures since surgery (Engel Class II) and 3% reported a worthwhile improvement (Engel Class III).
CONCLUSIONS: In contrast to previously described standard techniques for AH, the transsylvian-transcisternal approach presented in this study offers improved anatomical orientation and intraoperative control over the mesial temporal lobe and preserves the lateral as well as the laterobasal temporal lobe.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576254     DOI: 10.3171/jns.1998.88.5.0855

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  [Supratentorial cavernoma and epileptic seizures. Are there predictors for postoperative seizure control?].

Authors:  H Stefan; J Walter; F Kerling; I Blümcke; M Buchfelder
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

2.  Microsurgical anatomy of the transsylvian translimen insula approach to the mediobasal temporal lobe: Technical considerations and case illustration.

Authors:  David Straus; Richard W Byrne; Sepehr Sani; Anthony Serici; Roham Moftakhar
Journal:  Surg Neurol Int       Date:  2013-12-19

Review 3.  Surgical Treatment of Lesional Mesial Temporal Lobe Epilepsy.

Authors:  Sangjoon Chong; Ji Hoon Phi; Ji Yeoun Lee; Seung-Ki Kim
Journal:  J Epilepsy Res       Date:  2018-06-30

4.  Parietal transventricular approach for medial temporal glioma: A technical report.

Authors:  Amandeep Kumar; Poodipedi Chandra; Shashank Kale
Journal:  Surg Neurol Int       Date:  2020-02-14

5.  Microsurgical anatomy of the temporal lobe and its implications on temporal lobe epilepsy surgery.

Authors:  Baris Kucukyuruk; R Mark Richardson; Hung Tzu Wen; Juan Carlos Fernandez-Miranda; Albert L Rhoton
Journal:  Epilepsy Res Treat       Date:  2012-05-21

6.  Surgical Resection of Amygdala and Uncus.

Authors:  Naotaka Usui; Akihiko Kondo; Naoki Nitta; Takayasu Tottori; Yushi Inoue
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-08-09       Impact factor: 1.742

Review 7.  Epilepsy surgery, vision, and driving: what has surgery taught us and could modern imaging reduce the risk of visual deficits?

Authors:  Gavin P Winston
Journal:  Epilepsia       Date:  2013-09-20       Impact factor: 5.864

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.